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co-morbidities. No statistically significant association was observed between CPG 
2009 adherence and co-morbidities. CONCLUSIONS: The study explored the various 
aspects of prescribing pattern of physicians, their adherence to the CPG 2009 and 
the management of DM with other co-morbidities. This study also recognized the 
need for improvement in prescribers’ pattern of prescription and DM management 
with co-morbidities.
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OBJECTIVES: To compare the pivotal clinical endpoints on the prescribing informa-
tion labels of next generation treatments for type 2 diabetes (T2D) and to identify 
the most clinically-relevant antidiabetic outcomes. This multivariate analysis was 
designed to identify the appropriate treatment paradigm for the management of 
patients with T2D, based on symptomatology and relative efficacy. METHODS: 
A multivariate analysis of clinical efficacy endpoints from product information 
labels of 10 recently approved next generation treatments for adult T2D was under-
taken, with 26-week, placebo-controlled endpoint data for utilized all compounds, 
including change from baseline in hemoglobin A1c (%), body weight (kg), fasting 
plasma glucose (mg/dL), post-prandial plasma glucose (mg/dL), and the incidence 
of hypoglycemic events (%). Clinical relevance for this analysis was defined as 1% 
reduction in HbA1c, 5kg reduction in mean body weight from baseline, and an 
incidence of hypoglycemia < 1%. Data with metformin in combination therapy was 
included where available, based on current therapeutic guidelines. RESULTS: The 
multivariate analysis highlighted that no single compound met the predefined 
hypothesis of clinical relevance after 26-weeks of treatment. Canagliflozin 300mg 
/ metformin (-1.06%) and liraglutide (-1.00%) reported the greatest reduction in 
HbA1c. Canagliflozin 300mg / metformin (-4.07kg) and dapaglaflozin 10mg / met-
formin (-2.86kg) had the greatest mean reduction in body weight from baseline. 
Linagliptin 5mg / metformin (0.60%) and dapaglaflozin 10mg / metformin (1.10%) 
had the lowest incidence of hypoglycemia. CONCLUSIONS: Physicians should con-
sider all clinically-relevant outcomes of available T2D therapies with individual 
patient needs before initiating treatment. Clinicians must be aware of the various 
clinical outcomes for available therapies to ensure a safe and effective treatment 
regimen based on the symptomatic profile of individual patients. A triple-goal tar-
geted approach to the management of T2D may reduce healthcare costs and treat-
ment augmentation while improving quality of life for patients.
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OBJECTIVES: Various medications are commonly used to treat pain among indi-
viduals with type 2 diabetes mellitus (T2DM). This study examined the drug uti-
lization trends and factors associated with the use of pain medications among 
patients diagnosed with T2DM. METHODS: Data from the National Ambulatory 
Care Survey (NAMCS) 2006-2010 and the outpatient department component of the 
National Hospital Ambulatory Medical Care Survey (NHAMCS) were used to examine 
diabetes-related ambulatory visits among patients with T2DM. Bivariate chi-square 
analysis and multiple logistic regression were performed to evaluate the factors 
associated with prescribing of pain medications (e.g., anticonvulsants, antidepres-
sants, opioids and some topical agents). SAS survey procedures that adjust for the 
complex sampling procedure of NAMCS and NHAMCS were used. RESULTS: An 
average of 50 million (4.63%) visits was made by patients with T2DM from 2006 to 
2010. The majority of visits were made by females (54.84%), Whites (69.80%) and 
individuals aged 45-64 years (47.66%). Among patients with T2DM, 9.70% were pre-
scribed pain management drugs. The most commonly prescribed pain management 
drugs were anticonvulsants (4.51%), antidepressants (2.80%) and opioids (2.30%). 
Multiple logistic regression analysis showed that females (OR: 1.48; 95% CI: 1.19-
1.82), number of physician visits greater than 1 (OR: 1.39; 95% CI: 1.32-1.46), having 
private insurance (OR: 0.67; 95% CI: 0.49-0.90), and endocrinologist visit (OR: 0.68; 
95% CI: 0.51-0.89) are significant predictors of pain medication use among T2DM 
patients. CONCLUSIONS: Patients with T2DM were prescribed anticonvulsants two 
times more often as compared to opioids for pain management. Dispensed pre-
scriptions for pain medications were related to gender and number of physician 
visits. More frequent pain management related visits from patients over age 65 was 
consistent with the literature. Endocrinologist are less likely to prescribe medication 
for pain management than general medicine specialists.
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OBJECTIVES: To compare time to discontinuation with canagliflozin versus DPP-4 
inhibitors and GLP-1 agonists in patients with T2DM using retrospective claims 
data. METHODS: Patients with T2DM who received a first prescription for a DPP-4 
inhibitor (sitagliptin, saxagliptin, linagliptin), GLP-1 agonist (liraglutide, exenatide, 
exenatide long-acting), or an agent that inhibits SGLT2 (canagliflozin) in 2013 
were extracted from two US claims databases of commercially insured patients 
(Truven, Optum).  The analytical sample included only patients with ≥6 months 
of retrospective data prior to their first paid claim.  Discontinuation was defined 
as an observed refill gap ≥90 days (sensitivity analysis for 30/60 days) between 
BACKGROUND: Previous findings regarding the effect of depression treatment and 
its consequences on health related quality of life (HRQoL) of adults with diabetes 
were inconsistent and targeted certain groups of population. Therefore, there is 
a critical need to perform a study that focuses on a general population with dia-
betes and depression. OBJECTIVES: The primary aim of this study is to examine 
the physical and mental HRQoL associated with depression treatment. METHODS: 
We adopted a longitudinal design using multiple panels (2005-2011) of Medical 
Expenditure Panel Survey to create one year of baseline and one year of follow-
up. We categorized baseline depression treatment into no depression treatment, 
antidepressant use only and psychotherapy with or without antidepressants. We 
used perceived physical and mental health status during the follow-up year as 
measurements of HRQoL. Chi- square tests and multinomial logistic regressions 
were used to examine the association between depression treatment categories 
and HRQoL measures. In the adjusted analysis, we controlled for socio-demographic 
factors, lifestyle risk factors, other chronic conditions, and the baseline HRQoL 
measures. RESULTS: A significant association was observed between depression 
treatment and physical HRQoL measure in both unadjusted and adjusted models. 
Among adults who received psychotherapy (with or without antidepressants) 17.7% 
reported excellent /very good physical HRQoL while only 9.3% of those without 
depression treatment did so. In adjusted analyses, adults who received psycho-
therapy (with or without antidepressants) were more likely to report excellent/ very 
good health compared to those without depression treatment [adjusted OR = 2.32, 
95% CI = 1.01, 5.34]. For mental HRQoL, no significant differences were observed 
between treatment groups in the adjusted model. CONCLUSIONS: Depression treat-
ment, especially psychotherapy (with or without antidepressants) may improve 
physical HRQoL.
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OBJECTIVES: The aim of this study was to determine patient benefit-risk preference 
of insulin treatment, and to examine how preference is predicted by health literacy, 
sociodemographic status and patients own health risk perception. As a secondary 
objective we investigated whether elicited preferences were sensitive to the pres-
entation of benefits as either a surrogate or clinical health outcome METHODS: 
This was a questionnaire based study involving Danish type 2 diabetes patients 
recruited through a diabetes registry. Laboratory- and clinical data on diabetes 
management status was obtained from the registry. The questionnaire included 
a section on diabetes management, health literacy, demographics and a discrete 
choice experiment (DCE). In the DCE, respondents were asked to choose between 
two unlabelled insulin treatments. These were defined by improvements in glucose 
control (HbA1c or long-term sequelae risk reduction), weight control, hypoglycemic 
events (severe/minor) and treatment-related heart attack risk. A Baysian efficient 
design (Ngene v 1.1.1) was used to construct the choice tasks. Logistic regression 
analysis was used to describe the data relationships. Regression coefficients derived 
from this model were used to estimate maximum acceptable risk (MAR) of treatment 
in return of benefit. RESULTS: One thousand and thirty-three patients completed 
the questionnaire. Overall, the avoidance of a minor increase in heart-attack risk 
(3 additional people of 1000) was driving choice of treatment across all versions of 
the DCE. This was followed by avoiding severe hypoglycemic events. We observe 
some differences in preference estimates across the DCE versions indicating that 
patients are sensitive to the presentation of benefit as long-term sequelae risk 
reduction rather than a surrogate measure of health improvement (HbA1c). Detailed 
results on subgroup analysis and predictors of preference are presented at the 
conference. CONCLUSIONS: Risk-aversion of heart attack, although it is a minor 
additional risk, influence patient choice of treatment. Final conclusion is presented 
at the conference.
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OBJECTIVES: To evaluate the prescription pattern, adherence of prescribers with 
Clinical Practice Guideline 2009 and management of diabetes mellitus (DM) with co-
morbidities in a tertiary-care hospital, Pinang General Hospital Malaysia. METHODS: 
Cross-sectional study was performed on a total 51 prescribers and 1020 patients’ 
prescriptions written by the same prescribers (20 prescriptions for each prescriber). 
All 1020 DM patients were suffered with other co-morbidities. All of the prescrip-
tions were divided into two different groups i.e. adherent and non-adherent 
prescriptions. Self-administered research tools were used and demographic charac-
teristics of the patients were determined by descriptive statistics. Data was analyzed 
by using SPSS 21.0. Comparison between adherent and non-adherent groups was 
done by inferential statistics. RESULTS: In all prescriptions, overall good level of 
physician adherence was seen with respect to the recommendations of CPG 2009. A 
statistically significant negative association (Ф= 0.094, p-value= 0.003) was observed 
between DM management and co-morbidities. CPG adherent had shown statisti-
cally weak negative association (Ф= - 0.081, p-value= 0.010) with patients having 
